High-Dose HMG-CoA Inhibitor Simvastatin for Patients With Relapsed CLL: Pilot Trial and Pharmacokinetic-Pharmacodynamic Studies.

Trial Profile

High-Dose HMG-CoA Inhibitor Simvastatin for Patients With Relapsed CLL: Pilot Trial and Pharmacokinetic-Pharmacodynamic Studies.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2014

At a glance

  • Drugs Simvastatin (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacodynamics; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 14 Nov 2013 Planned end date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 17 Jul 2012 Planned end date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 23 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top